TIDMSN.
Smith & Nephew Plc
06 December 2017
Smith & Nephew to pilot digital wound care solution,
supporting Life Sciences Sector Deal
6 December 2017
Smith & Nephew (LSE:SN, NYSE:SNN), the global medical
technology business, welcomes the Life Sciences Sector Deal
released today and announces an innovative wound care programme to
support implementation.
Olivier Bohuon, Chief Executive Officer of Smith & Nephew,
said:
"The UK has a unique and world-class healthcare system with
significant potential to utilise medical technology in new ways to
improve clinical outcomes and efficiency. Through the closer
collaboration between healthcare providers and suppliers envisaged
by the Sector Deal, we can deliver benefits to the NHS that can
then be implemented in other health systems."
Smith & Nephew is developing new programmes that utilise
digital technology alongside its pioneering surgical and wound
management products with the aim to improve the patient experience
whilst delivering better outcomes at lower cost.
In wound care, Smith & Nephew is to pilot a new solution
addressing the cost of wound care for community nursing. This is
estimated to account for 66% of district nurse time, costing each
of the more than 200 Clinical Commissioning Groups ('CCGs') an
average of GBP50 million per annum by 2020(1) . Working with
partner Inhealthcare, a leading provider of digital health
technology, this includes a new digital tool to support frontline
community and practice nurses with point-of-care decision-making
support, to standardise best practice.
Over a three-year period, this programme is expected to:
-- Drive significant improvements in patient outcomes, resulting
in shorter treatment duration and more wounds healed
-- Release significant nurse resources, allowing them to cope
with growing patient numbers in the community, estimated at nine
full time nurses per CCG, and reduce the total costs of wound care
per CCG
-- Provide proof of principle that allows the approach to be
exported to international health systems.
These improvements will be driven by earlier and more systematic
intervention designed to reduce unnecessary dressing changes,
avoidable infections and unacceptable delays in healing.
Smith & Nephew is a global leader in advanced wound
management working to help our customers get closer to zero
surgical site complications, pressure ulcer incidence, delay in
wound healing, diabetic foot amputations, and waste of healthcare
resources. Our portfolio includes exudate and infection management,
negative pressure wound therapy, and bioactive products. In 2017 we
opened a new R&D centre in Hull and announced a long-term
partnership with the University of Hull to create one of the
world's largest Wound Care Research Clusters.
References:
1. The health economic burden that acute and chronic wounds
impose on an average clinical commissioning group/ health board in
the UK. J.F. Guest PhD, Director of Catalyst, Visiting Professor of
Health Economics; K. Vowden MSc, RN, Nurse Consultant; P. Vowden,
MD, FRCS, Consultant Vascular Surgeon, Professor of Wound Healing
Research. Journal of Wound Care 26/6 June 17.
ends
Enquiries
Investors
Ingeborg Øie
Smith & Nephew +44 (0) 20 7960 2285
Media
Charles Reynolds
Smith & Nephew +44 (0) 1923 477314
Ben Atwell/ Simon Conway
FTI Strategic Consulting +44 (0) 20 3727 1000
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2016 were
almost $4.7 billion. Smith & Nephew is a member of the FTSE 100
(LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com. For more information on our
approach to wound management please visit www.closertozero.com
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABSBDDLBGBGRL
(END) Dow Jones Newswires
December 06, 2017 09:19 ET (14:19 GMT)
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Mar 2023 to Mar 2024